In a report from Fierce Biotech yesterday, Silence Therapeutics, an RNAi company from London, shares increased by more than 75% on news that a suitor was in the wings to buy the company. Silence has confirmed that it has been approached but may or may not receive a purchase offer.
Silence extended a partnership in July with AstraZeneca Plc and is also working with Quark Pharmaceuticals and Novartis AG. Last year, the firm merged with the US company Intradigm Corporation in an all stock deal valued at $25 M.
The group also has a collaboration with the Japanese Dainippon Sumitomo Pharma that was signed last January. A Silence Therapeutics spokesman said that more information will be forthcoming in "due course". How British!
Posted by Bruce Lehr September 8th 2010.